Inicio › Linfoma no Hodgkin › Carolina del Norte
Ensayos clínicos de Linfoma no Hodgkin en Carolina del Norte
24 estudios sobre Linfoma no Hodgkin buscan participantes en Carolina del Norte.
Ciudades en Carolina del Norte
Texto oficial del estudio (inglés)
A Study to Evaluate Efficacy, Safety, and PK of XEMBIFY®+Standard Medical Treatment (SMT) Compared to Placebo+SMT to Prevent Infections in Participants With HGG and Recurrent or Severe Infections Associated With B-cell Chronic Lymphocytic Leukemia, Multiple Myeloma, and Non-Hodgkin Lymphoma
- GC2202 Study Site 109, Greenville
- GC2202 Decentralized Study Site 114, Morrisville
- GC2202 Study Site 117, Wilson
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 30 sept 2026 · NCT05645107TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
- Lineberger Comprehensive Cancer Center, Chapel Hill
- Atrium Health's Levine Cancer Institute, Charlotte
ReclutandoFase 2
Edades de 12 en adelante · Todos los sexos · Actualizado el 22 sept 2026 · NCT02693535Surovatamig (AZD0486) as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL
- Research Site, Charlotte
ReclutandoFase 2
Edades de 18 en adelante · Todos los sexos · Actualizado el 11 sept 2026 · NCT06526793Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma
- Atrium Health Wake Forest Baptist, Winston-Salem
ReclutandoFase 1/2
Edades de 18 en adelante · Todos los sexos · Actualizado el 25 ago 2026 · NCT05826535Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
- University of North Carolina at Chapel Hill/ University of North Carolina Medical Center, Chapel Hill
ReclutandoFase 1/2
Edades de 13 a 90 · Todos los sexos · Actualizado el 6 ago 2026 · NCT06533579Lentiviral Gene Therapy (Zamtocabtagene Autoleucel) LTFU
- Duke University Medical Center - Division of Hematologic Malignancies, Durham
ReclutandoEstudio observacional
Edades de 18 en adelante · Todos los sexos · Actualizado el 5 ago 2026 · NCT06116110A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy
- Duke Cancer Institute, Durham
- Atrium Health Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 4 ago 2026 · NCT07188558DALY II USA/ MB-CART2019.1 for DLBCL
- Duke University Medical Center - Division of Hematologic Malignancies, Durham
ReclutandoFase 2
Edades de 18 en adelante · Todos los sexos · Actualizado el 13 jul 2026 · NCT04792489Pre-malignant States to Hematologic Malignancies in Firefighters
- Levine Cancer Institute, Charlotte
ReclutandoEstudio observacionalSe aceptan voluntarios sanos
Edades de 40 a 49 · Todos los sexos · Actualizado el 13 jul 2026 · NCT06870760A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
- University of North Carolina at Chapel Hill, Chapel Hill
- Levine Children's Hospital, Charlotte
- Duke University Medical Center, Durham
ReclutandoEstudio observacional
Todas las edades · Todos los sexos · Actualizado el 6 jul 2026 · NCT01351545Registry of Older Patients With Cancer
- Seby B. Jones Cancer Center, Boone
- Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill
- East Carolina University, Greenville
- y 4 más
ReclutandoEstudio observacional
Edades de 65 en adelante · Todos los sexos · Actualizado el 29 jun 2026 · NCT01137825Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.
- University of North Carolina, Chapel Hill
ReclutandoFase 1
Edades de 13 en adelante · Todos los sexos · Actualizado el 5 may 2026 · NCT04771572CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
- Duke University Medical Center, Duke Cancer Center, Durham
ReclutandoFase 1/2
Edades de 18 en adelante · Todos los sexos · Actualizado el 16 abr 2026 · NCT03328078The Prospective Collection, Storage and Reporting of Data on Patients Undergoing Hematopoietic Stem Cell Transplantation Utilizing a Standard Preparative Regimen
- Wake Forest Baptist Health, Winston-Salem
ReclutandoEstudio observacional
Edades de 18 a 120 · Todos los sexos · Actualizado el 13 abr 2026 · NCT01890486Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
- Atrium Health Stanly/LCI-Albemarle, Albemarle
- Cone Health MedCenter Asheboro, Asheboro
- Cone Health Cancer Center at Alamance Regional, Burlington
- y 21 más
ReclutandoEstudio observacional
Edades de 18 en adelante · Todos los sexos · Actualizado el 17 mar 2026 · NCT06418204A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib
- Duke University Medical Center, Durham
ReclutandoFase 4
Edades de 18 en adelante · Todos los sexos · Actualizado el 2 mar 2026 · NCT06876649A Study of (LY3527727) Pirtobrutinib in Participants With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma
- Duke University Medical Center, Durham
ReclutandoFase 4
Edades de 18 en adelante · Todos los sexos · Actualizado el 2 mar 2026 · NCT06876662Study of SGR-1505 in Mature B-Cell Neoplasms
- Duke University, Durham
ReclutandoFase 1
Edades de 18 en adelante · Todos los sexos · Actualizado el 13 feb 2026 · NCT05544019A Safety and Efficacy Study of HCB101, Fc-fusion Protein Targeting SIRPα-CD47 Pathway, in Solid or Hematological Tumors
- Carolina BioOncology, Huntersville
ReclutandoFase 1
Edades de 18 en adelante · Todos los sexos · Actualizado el 4 feb 2026 · NCT05892718AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma
- Duke University, Durham
ReclutandoFase 1
Edades de 18 en adelante · Todos los sexos · Actualizado el 10 dic 2025 · NCT05602363SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Chapel Hill
- Massive Bio SYNERGY-AI site, Winston-Salem
ReclutandoEstudio observacional
Todas las edades · Todos los sexos · Actualizado el 28 oct 2025 · NCT03452774Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic Cancer
- Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill
ReclutandoEstudio observacional
Edades de 18 a 120 · Todos los sexos · Actualizado el 27 oct 2025 · NCT01137643A Study of AC676 for the Treatment of Relapsed/Refractory B-Cell Malignancies
- University of North Carolina, Chapel Hill
ReclutandoFase 1
Edades de 18 en adelante · Todos los sexos · Actualizado el 2 oct 2025 · NCT05780034IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers
- Atrium Health Wake Forest Baptist, Winston-Salem
ReclutandoFase 1/2
Edades de 18 en adelante · Todos los sexos · Actualizado el 3 jun 2025 · NCT06119685De ClinicalTrials.gov, datos obtenidos el 6 oct 2026. Cada estudio establece sus propios criterios de elegibilidad; el equipo del estudio decide quién puede participar.